Title:
ウイルス株
Document Type and Number:
Japanese Patent JP6644378
Kind Code:
B2
Abstract:
The present invention relates to the use of a modified, oncolytic, herpes simplex virus (HSV) strain in the manufacture of a medicament for the oncolytic treatment of cancer, which HSV strain:
(a) has a greater ability than HSV1 17+, HSV1 F and HSV1 KOS strains with equivalent modifications to replicate in or kill tumour cells; and
(b) is obtainable by isolating an HSV strain from a host and modifying the isolated HSV strain to provide for selective replication in tumour cells.
Inventors:
Coffin, robert, stewart
Application Number:
JP2018218735A
Publication Date:
February 12, 2020
Filing Date:
November 22, 2018
Export Citation:
Assignee:
Bio Vex Limited
International Classes:
A61K35/763; C12N7/04; A61K31/7105; A61K38/00; A61K38/19; A61K38/44; A61K48/00; A61P25/00; A61P25/02; A61P31/00; A61P35/00; A61P37/04; A61P43/00; C12N7/00; C12N7/01; C12N15/869; C12Q1/02; C12Q1/68; A61K39/00; A61K; C12N; C12Q
Domestic Patent References:
| JP4921669B2 | ||||
| JP4810042B2 |
Foreign References:
| WO1999007394A1 | ||||
| WO1998004726A1 | ||||
| WO1998051809A1 |
Other References:
Gene Ther.,1998年,vol.5, no.1,pp.121-130
Proc. Natl. Acad Sci. USA,1995年,vol.92, no.5,pp.1411-1415
N. Engl. J. Med.,1991年,vol.325, no.15,pp.1082-1085
Proc. Natl. Acad Sci. USA,1995年,vol.92, no.5,pp.1411-1415
N. Engl. J. Med.,1991年,vol.325, no.15,pp.1082-1085
Attorney, Agent or Firm:
Yusuke Hiraki
Satoshi Fujita
Natsuo Tanaka
Satoshi Fujita
Natsuo Tanaka